# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Bruce Jackson reiterates Biolase (NASDAQ:BIOL) with a Speculative Buy and maintains $0.4 price target.
Biolase (NASDAQ:BIOL) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.17) by ...
Ascendiant Capital analyst Edward Woo maintains Biolase (NASDAQ:BIOL) with a Buy and lowers the price target from $15 to $4.
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected four...